Inventor · disambiguated record
Agostino Marasco
Also filed as: MARASCO AGOSTINO
29 granted patents·9 pending applications·118 citations·filing 2006–2025
96Inventor score
Files withAUTIFONY THERAPEUTICS LTD27ALVARO GIUSEPPE3NERRE THERAPEUTICS LTD3GLAXO WELLCOME MFG PTE LTD2AUTIFONY THERAPUTICS LTD1
Top patents by PatentIndex Score
38 records- 0195US10835534B2CompoundsAUTIFONY THERAPEUTICS LTD·Filed 2019·Granted Nov 17, 2020·3 cites·4 claims
- 0295US9422272B2CompoundsAUTIFONY THERAPEUTICS LTD·Filed 2015·Granted Aug 23, 2016·11 cites·2 claims
- 0395US9133175B2CompoundsAUTIFONY THERAPEUTICS LTD·Filed 2012·Granted Sep 15, 2015·18 cites·10 claims
- 0494US10098881B2CompoundsAUTIFONY THERAPEUTICS LTD·Filed 2017·Granted Oct 16, 2018·8 cites·14 claims
- 0593US9833452B2CompoundsAUTIFONY THERAPEUTICS LTD·Filed 2016·Granted Dec 5, 2017·7 cites·1 claims
- 0693US9346790B2Hydantoin derivatives useful as Kv3 inhibitorsALVARO GIUSEPPE·Filed 2011·Granted May 24, 2016·16 cites·18 claims
- 0789US8722695B2Imidazolidinedione derivativesALVARO GIUSEPPE·Filed 2010·Granted May 13, 2014·9 cites·16 claims
- 0888US10555945B2CompoundsAUTIFONY THERAPEUTICS LTD·Filed 2018·Granted Feb 11, 2020·3 cites·17 claims
- 0988US7855218B2CompoundsCONVERGENCE PHARMACEUTICALS·Filed 2006·Granted Dec 21, 2010·13 cites·16 claims
- 1087US9849131B2Imidazolidinedione derivativesAUTIFONY THERAPEUTICS LTD·Filed 2016·Granted Dec 26, 2017·4 cites·19 claims
- 1186US11197859B2Hydantoin derivatives useful as Kv3 inhibitorsAUTIFONY THERAPEUTICS LTD·Filed 2020·Granted Dec 14, 2021·1 cites·16 claims
- 1286US9216967B2Imidazolidinedione derivativesAUTIFONY THERAPEUTICS LTD·Filed 2014·Granted Dec 22, 2015·5 cites·7 claims
- 1385US10058551B2Imidazolidinedione derivativesAUTIFONY THERAPEUTICS LTD·Filed 2017·Granted Aug 28, 2018·3 cites·12 claims
- 1484US9422252B2Triazoles as Kv3 inhibitorsAUTIFONY THERAPEUTICS LTD·Filed 2013·Granted Aug 23, 2016·5 cites·5 claims
- 1583US9193704B2Hydantoin derivatives as KV3 inhibitorsALVARO GIUSEPPE·Filed 2012·Granted Nov 24, 2015·6 cites·11 claims
- 1683US8344005B25-[5-[2-(3,5-bis(trifluoromethyl)phenyl)-2-methylpropanoMethylpropanoylmethylamino]-4-(4-fluoro-2-methylphenyl)]-2 as NK1 receptor antagonistsGLAXO WELLCOME MFG PTE LTD·Filed 2009·Granted Jan 1, 2013·5 cites·5 claims
- 1780US11583527B2Hydantoin derivatives useful as Kv3 inhibitorsAUTIFONY THERAPEUTICS LTD·Filed 2021·Granted Feb 21, 2023·0 cites·18 claims
- 1880US10265316B2Hydantoin derivatives useful as Kv3 inhibitorsAUTIFONY THERAPEUTICS LTD·Filed 2017·Granted Apr 23, 2019·1 cites·3 claims
- 1977US11541052B2CompoundsAUTIFONY THERAPEUTICS LTD·Filed 2020·Granted Jan 3, 2023·0 cites·7 claims
- 2073US11180461B2Triazoles as Kv3 inhibitorsAUTIFONY THERAPEUTICS LTD·Filed 2020·Granted Nov 23, 2021·0 cites·5 claims
- 2171US12358901B2KV3 modulatorsAUTIFONY THERAPEUTICS LTD·Filed 2021·Granted Jul 15, 2025·0 cites·3 claims
- 2271US2025304564A1Novel kv3 modulatorsAUTIFONY THERAPEUTICS LTD·Filed 2025·Application pending·0 cites
- 2370US2020163964A1Imidazolidinedione derivativesAUTIFONY THERAPEUTICS LTD·Filed 2020·Application pending·0 cites
- 2470US2019192516A1Hydantoin derivatives useful as kv3 inhibitorsAUTIFONY THERAPEUTICS LTD·Filed 2019·Application pending·0 cites
- 2568US10611735B2Triazoles as Kv3 inhibitorsAUTIFONY THERAPEUTICS LTD·Filed 2018·Granted Apr 7, 2020·0 cites·5 claims
- 2664US10632118B2Imidazolidinedione derivativesAUTIFONY THERAPUTICS LTD·Filed 2018·Granted Apr 28, 2020·0 cites·20 claims
- 2763US9006271B25-[5-[2-(3,5-bis(trifluoromethyl)phenyl)-2-methylpropanomethylpropanoylmethylamino]-4-(4-fluoro-2-methylphenyl)]-2-pyridinyl-2-alkyl-prolinamide as NK1 receptor antagonistsNERRE THERAPEUTICS LTD·Filed 2014·Granted Apr 14, 2015·0 cites·13 claims
- 2862US2016251340A1Hydantoin derivatives useful as kv3 inhibitorsAUTIFONY THERAPEUTICS LTD·Filed 2016·Application pending·0 cites
- 2960US8822504B25-[5-[2-(3,5-bis(trifluoromethyl)phenyl)-2-methylpropanomethylpropanoylmethylamino]-4-(4-fluoro-2-methylphenyl)]-2-pyridinyl-2-alkyl-prolinamide as NK1 receptor antagonistsNERRE THERAPEUTICS LTD·Filed 2012·Granted Sep 2, 2014·0 cites·5 claims
- 3059US2024327406A1Potassium channel modulatorsAUTIFONY THERAPEUTICS LTD·Filed 2022·Application pending·0 cites
- 3158US2016058737A1Imidazolidinedione derivativesAUTIFONY THERAPEUTICS LTD·Filed 2015·Application pending·0 cites
- 3257US8367692B2Spiro (piperidine-4,2′-pyrrolidine)-1-(3,5-trifluoromethyl phenyl) methylcarboxamides as NK1 tachikynin receptor antagonistsGLAXO WELLCOME MFG PTE LTD·Filed 2009·Granted Feb 5, 2013·0 cites·13 claims
- 3356US10160730B2Triazoles as KV3 inhibitorsAUTIFONY THERAPEUTICS LTD·Filed 2016·Granted Dec 25, 2018·0 cites·30 claims
- 3449US8633214B2Spiro (piperidine-4,2′-pyrrolidine)-1-(3,5-trifluoromethylphenyl) methylcarboxamides as NK1 tachikynin receptor antagonistsNERRE THERAPEUTICS LTD·Filed 2012·Granted Jan 21, 2014·0 cites·6 claims
- 3549US2010130583A1Prolinamide derivatives as modulators of voltage-gated sodium channelsGLAXO GROUP LTD·Filed 2008·Application pending·0 cites
- 3643US2020039970A1Hydantoin modulators of kv3 channelsAUTIFONY THERAPEUTICS LTD·Filed 2017·Application pending·0 cites
- 3740US2020377485A1Hydantoin modulators of kv3 channelsAUTIFONY THERAPEUTICS LTD·Filed 2016·Application pending·0 cites
- 3837US10934278B2CompoundsAUTIFONY THERAPEUTICS LTD·Filed 2017·Granted Mar 2, 2021·0 cites·18 claims
Join the waitlist — get patent alerts
Get an alert when Agostino Marasco files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →